A carregar...
Evaluation of Apixaban for the Treatment of Nonvalvular Atrial Fibrillation With Regard to Dosing and Safety in a Community Hospital
Background: Apixaban, a direct factor Xa inhibitor, is approved by the US Food and Drug Administration (FDA) for prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Apixaban’s compelling safety and efficacy data, combined with minimal laboratory monitoring, make it an attr...
Na minha lista:
| Publicado no: | J Pharm Technol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5998530/ https://ncbi.nlm.nih.gov/pubmed/34860985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/8755122517706423 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|